[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]

Aktuelle Urol. 2013 Jan;44(1):45-9. doi: 10.1055/s-0032-1323745. Epub 2012 Sep 26.
[Article in German]


Targeted therapies such as sunitinib, pazopanib, bevacizumab, sorafenib and everolimus have become established as new therapeutic standards in the treatment of metastatic renal cell carcinoma. New substances are going to complement these treatment options. Therefore, cytokines as long-term standard therapy are being more and more replaced. The achievements raise a lot of questions in clinical daily routine: Which criteria influence the decision for therapy? How can a remission be assessed when antiangiogenetic agents are administered? And last but not least, the optimal sequence remains a controversially discussed topic. Based on the current study situation, an interdisciplinary expert meeting was held to debate these aspects. Results from the 2010 conference provided the basis for the 2011 meeting. The results of the 2011 conference are presented as short theses.

Publication types

  • Consensus Development Conference
  • English Abstract

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / therapy*
  • Combined Modality Therapy
  • Cooperative Behavior*
  • Disease Progression
  • Drug Delivery Systems
  • Humans
  • Interdisciplinary Communication*
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy
  • Nephrectomy
  • Prognosis
  • Randomized Controlled Trials as Topic


  • Antineoplastic Agents

Supplementary concepts

  • Clear-cell metastatic renal cell carcinoma